Search company, investor...

Exodos Life Sciences


Unattributed | Alive

Total Raised


Last Raised

$690K | 9 yrs ago

About Exodos Life Sciences

Exodos Life Sciences is a pharmaceutical development company that focuses on advancing new product concepts through the 505(b)(2) process to early clinical proof of principle followed by asset (project) sale. Exodos has adopted a semi-virtual model to control costs and advance projects by utilizing its experienced team and on-call external pharmaceutical experts and partners.

Headquarters Location

6340 Quadrangle Drive Suite 120

Chapel Hill, North Carolina, 27517,

United States


Missing: Exodos Life Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Exodos Life Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Exodos Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exodos Life Sciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Exodos Life Sciences Patents

Exodos Life Sciences has filed 6 patents.

The 3 most popular patent topics include:

  • Animal fungal diseases
  • Antifungals
  • Antiseptics
patents chart

Application Date

Grant Date


Related Topics




Antifungals, Animal fungal diseases, Morpholines, Fungicides, Antiseptics


Application Date


Grant Date



Related Topics

Antifungals, Animal fungal diseases, Morpholines, Fungicides, Antiseptics



Latest Exodos Life Sciences News

Global Raynaud's Disease Pipeline Report 2020 Featuring Allergan, Apricus Biosciences, Exodos Life Sciences and Pfizer

Jul 29, 2020

News provided by Share this article PIPELINE HIGHLIGHTS Raynauds Disease is one of the widely researched conditions during 2020 with 4 companies actively focusing on realizing pipeline's potential. Development of Raynauds Disease medicines is identified as integral to the strategy of the majority of companies operating in the industry. Global Raynauds Disease market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Raynauds Disease. Good progress is anticipated during 2020 and 2021 with Raynauds Disease pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Raynauds Disease pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies. DRUG DEVELOPMENT PIPELINE OVERVIEW The Raynauds Disease pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook. This Raynauds Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression. The competitive intelligence report on Raynauds Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Raynauds Disease pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report. DRUG PROFILES Raynauds Disease development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided: Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. Phase of development New molecular entity details COMPANY PROFILES Both small size and large size pharmaceutical companies are investing their resources in Raynauds Disease drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Raynauds Disease. Partnerships and acquisitions are also increasingly observed in the pipeline. This research report presents an analysis of 4 Raynauds Disease companies including company overview, key snapshot, contact information, and their strategies on accelerating Raynauds Disease pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report. Reasons to Buy The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment. This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data Buyers can identify most promising drug candidates for treatment of Raynauds Disease It allows users to strengthen their pipeline through acquisitions, licensing and collaborations Users can estimate possible delays in the delivery of pipeline or launch of new products Stay ahead of competition through understanding their pipeline progression, strategies and outlook The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches. Optimize your licensing and technology transfer strategies through identification of prospect partners Companies Analyzed

Exodos Life Sciences Frequently Asked Questions (FAQ)

  • Where is Exodos Life Sciences's headquarters?

    Exodos Life Sciences's headquarters is located at 6340 Quadrangle Drive, Chapel Hill.

  • What is Exodos Life Sciences's latest funding round?

    Exodos Life Sciences's latest funding round is Unattributed.

  • How much did Exodos Life Sciences raise?

    Exodos Life Sciences raised a total of $1.94M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.